Covid-19 Research

Review Article

OCLC Number/Unique Identifier:

RUCAM-Ascertained Immunology and Autoimmunity Specifics of Idiosyncratic Drug-Induced Liver Injury: A Complex Molecular Interplay

Medicine Group
Immunology
Pharmacology
Hepatology
   Start Submission

Rolf Teschke

Volume6-Issue11
Dates: Received: 2025-10-24 | Accepted: 2025-11-29 | Published: 2025-11-30
Pages: 1810-1851

Abstract

Idiosyncratic Drug-Induced Liver Injury iDILI) is not a uniform disease but rather includes a variety of types based on immune, autoimmune, and clinical considerations. This review attempts to close information gaps regarding the role of immunity and autoimmunity involved in causing the different iDILI disease types. The analysis of the current literature with focus on iDILI reveals that compelling evidence suggests a pivotal role of immunity or autoimmunity in various types of iDILI. Among the autoimmune-triggered ones are the Drug-Induced Autoimmune Hepatitis (DIAIH) and the idiosyncratic drug-induced anti-CYP autoimmune hepatitis. As opposed, clearly immune-triggered are the Human Leucocyte Antigen (HLA)-based immune iDILI, the immune iDILI with Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), and the immune iDILI by Immune Checkpoint Inhibitors (ICIs), but immune-triggered is only a part of the classic iDILI cases. For all these iDILI types, the use of the original or updated Roussel Uclaf Causality Assessment Method (RUCAM) allowed for confirming causality of the implicated drug, assisted by the simplified Autoimmune Hepatitis (AIH) score in the DIAIH cases and the Algorithm of Drug Causality for Epidermal Necrolysis (ALDEN) score in the cases of immune-based iDILI with SJS/TEN. All these diagnostic causality assessment algorithms are validated methods and helped define clinical features of the different iDILI types. The first treatment goal is the cessation of the suspected drug, which alone may lead to clinical and laboratory improvement and restoration of health. However, a therapy with immunosuppressant agents is often needed to treat the injury caused by immune and autoimmune processes and can lead to complete remission in all iDILI types with the exemption of the classic IDILI where only parts of the patients achieve remission. At the molecular pathomechanistic level, there is a complex interplay mostly related to the adaptive innate immune system activated by the innate system. In sum, immunology and autoimmunity specifics in cases of RUCAM-ascertained iDILI types remain a challenging topic that can be deepened by future cases if validated diagnostic algorithms are applied.

FullText HTML FullText PDF DOI: 10.37871/jbres2232

Certificate of Publication

Copyright

© 2025 Teschke R, et al. Distributed under Creative Commons CC-BY 4.0

How to cite this article

Teschke R. RUCAM-Ascertained Immunology and Autoimmunity Specifi cs of Idiosyncratic Drug-Induced Liver Injury: A Complex Molecular Interplay. J Biomed Res Environ Sci. 2025 Nov 30; 6(11): 1810-1851. doi: 10.37871/jbres2232, Article ID: JBRES2232, Available at: https://www.jelsciences.com/articles/jbres2232.pdf

Subject area(s)

Immunology
Pharmacology
Hepatology

References

  1. Uetrecht J. Mechanisms of idiosyncratic drug-induced liver injury. Adv Pharmacol. 2019;85:133-163. doi: 10.1016/bs.apha.2018.12.001. Epub 2019 Jan 18. PMID: 31307585.
  2. Uetrecht J. DILI prediction in drug development: present and future. Expert Opin Drug Metab Toxicol. 2025 Jun;21(6):665-676. doi: 10.1080/17425255.2025.2495955. Epub 2025 Apr 20. PMID: 40253704.
  3. Teschke R, Uetrecht J. Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues. Ann Transl Med. 2021 Apr;9(8):730. doi: 10.21037/atm-2020-ubih-05. PMID: 33987428; PMCID: PMC8106057.
  4. Teschke R. Immunology highlights of four major idiosyncratic DILI subtypes verified by the RUCAM: a new evidence-based classification. Livers. 2025; 5: 8. doi: 10.3390/livers5010008.
  5. Danan G, Benichou C. Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol. 1993 Nov;46(11):1323-30. doi: 10.1016/0895-4356(93)90101-6. PMID: 8229110.
  6. Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol. 1993 Nov;46(11):1331-6. doi: 10.1016/0895-4356(93)90102-7. PMID: 8229111.
  7. Danan G, Teschke R. RUCAM in Drug and Herb Induced Liver Injury: The Update. Int J Mol Sci. 2015 Dec 24;17(1):14. doi: 10.3390/ijms17010014. PMID: 26712744; PMCID: PMC4730261.
  8. Teschke R, Eickhoff A, Danan G. Drug-Induced Autoimmune Hepatitis: Robust Causality Assessment Using Two Different Validated and Scoring Diagnostic Algorithms. Diagnostics (Basel). 2025 Jun 23;15(13):1588. doi: 10.3390/diagnostics15131588. PMID: 40647587; PMCID: PMC12249124.
  9. Teschke R, Danan G. Idiosyncratic DILI and RUCAM under one hat: the global view. Livers. 2023; 3: 397-434. doi: 10.3390/livers3030030.
  10. Teschke R, Danan G. Advances in Idiosyncratic Drug-Induced Liver Injury Issues: New Clinical and Mechanistic Analysis Due to Roussel Uclaf Causality Assessment Method Use. Int J Mol Sci. 2023 Jun 29;24(13):10855. doi: 10.3390/ijms241310855. PMID: 37446036; PMCID: PMC10341975.
  11. Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, Krawitt EL, Bittencourt PL, Porta G, Boberg KM, Hofer H, Bianchi FB, Shibata M, Schramm C, Eisenmann de Torres B, Galle PR, McFarlane I, Dienes HP, Lohse AW; International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology. 2008 Jul;48(1):169-76. doi: 10.1002/hep.22322. PMID: 18537184.
  12. Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K, Haustein UF, Vieluf D, Roujeau JC, Le Louet H. ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010 Jul;88(1):60-8. doi: 10.1038/clpt.2009.252. Epub 2010 Apr 7. PMID: 20375998.
  13. Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology. 2005 Aug;42(2):481-9. doi: 10.1002/hep.20800. PMID: 16025496.
  14. Naseralallah LM, Aboujabal BA, Geryo NM, Al Boinin A, Al Hattab F, Akbar R, Umer W, Abdul Jabbar L, Danjuma MI. The determination of causality of drug induced liver injury in patients with COVID-19 clinical syndrome. PLoS One. 2022 Sep 1;17(9):e0268705. doi: 10.1371/journal.pone.0268705. PMID: 36048762; PMCID: PMC9436150.
  15. Bishop B, Hannah N, Doyle A, Amico F, Hockey B, Moore D, Sood S, Gorelik A, Liew D, Njoku D, Nicoll A. A prospective study of the incidence of drug-induced liver injury by the modern volatile anaesthetics sevoflurane and desflurane. Aliment Pharmacol Ther. 2019 Apr;49(7):940-951. doi: 10.1111/apt.15168. Epub 2019 Feb 13. PMID: 30761577.
  16. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 31643176.
  17. Ke L, Lu C, Shen R, Lu T, Ma B, Hua Y. Knowledge Mapping of Drug-Induced Liver Injury: A Scientometric Investigation (2010-2019). Front Pharmacol. 2020 Jun 5;11:842. doi: 10.3389/fphar.2020.00842. PMID: 32581801; PMCID: PMC7291871.
  18. Andrade RJ, Lucena MI, Fernández MC, Pelaez G, Pachkoria K, García-Ruiz E, García-Muñoz B, González-Grande R, Pizarro A, Durán JA, Jiménez M, Rodrigo L, Romero-Gomez M, Navarro JM, Planas R, Costa J, Borras A, Soler A, Salmerón J, Martin-Vivaldi R; Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology. 2005 Aug;129(2):512-21. doi: 10.1016/j.gastro.2005.05.006. Erratum in: Gastroenterology. 2005 Nov;129(5):1808. PMID: 16083708.
  19. Teschke R, Danan G. Worldwide Use of RUCAM for Causality Assessment in 81,856 Idiosyncratic DILI and 14,029 HILI Cases Published 1993-Mid 2020: A Comprehensive Analysis. Medicines (Basel). 2020 Sep 29;7(10):62. doi: 10.3390/medicines7100062. PMID: 33003400; PMCID: PMC7600114.
  20. Teschke R. Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the Roussel Uclaf Causality Assessment Method. Expert Opin Drug Metab Toxicol. 2018 Nov;14(11):1169-1187. doi: 10.1080/17425255.2018.1539077. Epub 2018 Oct 29. PMID: 30354694.
  21. Abeles RD, Foxton M, Khan S, Goldin R, Smith B, Thursz MR, Verma S. Androgenic anabolic steroid-induced liver injury: two case reports assessed for causality by the updated Roussel Uclaf Causality Assessment Method (RUCAM) score and a comprehensive review of the literature. BMJ Open Gastroenterol. 2020 Nov;7(1):e000549. doi: 10.1136/bmjgast-2020-000549. PMID: 33214235; PMCID: PMC7678230.
  22. Andújar-Vera F, Alés-Palmer ML, Muñoz-de-Rueda P, Iglesias-Baena I, Ocete-Hita E. Metabolomic Analysis of Pediatric Patients with Idiosyncratic Drug-Induced Liver Injury According to the Updated RUCAM. Int J Mol Sci. 2023 Sep 1;24(17):13562. doi: 10.3390/ijms241713562. PMID: 37686369; PMCID: PMC10487599.
  23. Chamay S, Alter A, Parikh R, Khatri S, Budh D, Spinnell M. Methimazole-induced cholestasis initially obscured by an incidental finding of a large periampullary diverticulum: A case report with reference to the updated RUCAM of 2016. JGH Open. 2025 Feb 24;9(2):e13042. doi: 10.1002/jgh3.13042. PMID: 40007940; PMCID: PMC11850431.
  24. Chen Y, Wang C, Yang H, Huang P, Shi J, Tong Y, Jiang J, Zhang X, Chen W, Xuan Z. Epidemiology of Drug- and Herb-Induced Liver Injury Assessed for Causality Using the Updated RUCAM in Two Hospitals from China. Biomed Res Int. 2021 Feb 24;2021:8894498. doi: 10.1155/2021/8894498. PMID: 33954202; PMCID: PMC8067772.
  25. Danjuma MI, Almasri H, Alshokri S, Khir FK, Elmalik A, Battikh NG, Abdallah IMH, Elshafei M, Fatima H, Mohamed MFH, Maghoub Y, Hussain T, Kamal I, Anwer Z, Bidmos MA, Elzouki AN. Avoidability of drug-induced liver injury (DILI) in an elderly hospital cohort with cases assessed for causality by the updated RUCAM score. BMC Geriatr. 2020 Sep 14;20(1):346. doi: 10.1186/s12877-020-01732-3. PMID: 32928134; PMCID: PMC7489200.
  26. Díaz-Orozco L, Quiroz-Compean F, Aquino-Matus J, Teschke R, Méndez-Sánchez N. Severe DILI in a patient under polypharmacy including rosuvastatin: diagnostic challenges and lessons from a case report assessed using the updated RUCAM algorithm. Int J Gastroenterol Hepatol Dis. 2022; 10: e250422203997. doi: 10.2174/2666290601666220425104715.
  27. Hountondji L, Faure S, Palassin P, Viel PWD, Dupuy M, Larrey D, Lamoureux A, Coustal C, Pureur D, Lesage C, Assenat É, Rivière B, Faillie JL, Quantin X, Pageaux GP, Maria ATJ, Meunier L. Time to use the right classification to predict the severity of checkpoint inhibitor-induced liver injury, as assessed for causality using the updated RUCAM. Aliment Pharmacol Ther. 2024 Dec;60(11-12):1561-1572. doi: 10.1111/apt.18276. Epub 2024 Sep 24. PMID: 39315730; PMCID: PMC11599793.
  28. Kobayashi T, Iwaki M, Nogami A, Yoneda M. Epidemiology and Management of Drug-induced Liver Injury: Importance of the Updated RUCAM. J Clin Transl Hepatol. 2023 Oct 28;11(5):1239-1245. doi: 10.14218/JCTH.2022.00067S. Epub 2023 Apr 28. PMID: 37577239; PMCID: PMC10412691.
  29. Lischka W, Kriegshäuser G. Drug-induced liver injury as assessed by the updated Roussel Uclaf Causality Assessment Method following mild COVID-19 in a patient under anastrozole therapy-A case report. Cancer Rep (Hoboken). 2024 Apr;7(4):e2028. doi: 10.1002/cnr2.2028. PMID: 38577842; PMCID: PMC10995933.
  30. Mascherona I, Maggioli C, Biggiogero M, Mora O, Marelli L. A Severe Case of Drug-Induced Liver Injury after Gemcitabine Administration: A Highly Probable Causality Grading as Assessed by the Updated RUCAM Diagnostic Scoring System. Case Reports Hepatol. 2020 Oct 1;2020:8812983. doi: 10.1155/2020/8812983. PMID: 33083070; PMCID: PMC7556098.
  31. Plüß M, Tampe D, Schwörer H, Bremer SCB, Tampe B. Case report: Kinetics of human leukocyte antigen receptor HLA-DR during liver injury induced by potassium para-aminobenzoate as assessed for causality using the updated RUCAM. Front Pharmacol. 2022 Aug 17;13:966910. doi: 10.3389/fphar.2022.966910. PMID: 36059975; PMCID: PMC9428317.
  32. Qin FL, Sang GY, Zou XQ, Cheng DH. Drug-Induced Liver Injury during Consolidation Therapy in Childhood Acute Lymphoblastic Leukemia as Assessed for Causality Using the Updated RUCAM. Can J Gastroenterol Hepatol. 2022 Mar 24;2022:5914593. doi: 10.1155/2022/5914593. PMID: 35369115; PMCID: PMC8970867.
  33. Shi H, Chen R, Li M, Ge J. Acute hepatotoxicity of intravenous amiodarone in a Becker muscular dystrophy patient with decompensated heart failing and ABCB4 gene mutation: as assessed for causality using the updated RUCAM. J Cardiothorac Surg. 2024 Jul 23;19(1):464. doi: 10.1186/s13019-024-02869-7. PMID: 39044225; PMCID: PMC11265456.
  34. Shi X, Zuo C, Yu L, Lao D, Li X, Xu Q, Lv Q. Real-World Data of Tigecycline-Associated Drug-Induced Liver Injury Among Patients in China: A 3-year Retrospective Study as Assessed by the Updated RUCAM. Front Pharmacol. 2021 Nov 2;12:761167. doi: 10.3389/fphar.2021.761167. PMID: 34795591; PMCID: PMC8594628.
  35. Tewkesbury D, Jones AM, Bright-Thomas R, Cratchley A, Hanley KP, Wyatt J, Athwal V, Barry PJ. Aetiology of Significant Liver Test Abnormalities in a Single-Centre Cohort of People with Cystic Fibrosis Exposed to Elexacaftor/Tezacaftor/Ivacaftor, Utilizing the Updated RUCAM. Drugs. 2023 Dec;83(18):1699-1707. doi: 10.1007/s40265-023-01969-3. Epub 2023 Nov 15. PMID: 37966582.
  36. Tzadok R, Levy S, Aouizerate J, Shibolet O. Acute Liver Failure following a Single Dose of Atezolizumab, as Assessed for Causality Using the Updated RUCAM. Case Rep Gastrointest Med. 2022 Mar 23;2022:5090200. doi: 10.1155/2022/5090200. PMID: 35368450; PMCID: PMC8967548.
  37. Wang MG, Wu SQ, Zhang MM, He JQ. Urine metabolomics and microbiome analyses reveal the mechanism of anti-tuberculosis drug-induced liver injury, as assessed for causality using the updated RUCAM: A prospective study. Front Immunol. 2022 Nov 22;13:1002126. doi: 10.3389/fimmu.2022.1002126. PMID: 36483548; PMCID: PMC9724621.
  38. Wang P, Guo G, Jiang S, Ding D, Yang J, Lu Y, Han Y, Zhou X. Glucocorticoids accelerate the reduction of disease severity and biochemical parameters in drug-induced liver injury: Assess the causal relationship using the updated RUCAM scale. Clin Res Hepatol Gastroenterol. 2025 Jul-Aug;49(7):102635. doi: 10.1016/j.clinre.2025.102635. Epub 2025 Jun 7. PMID: 40490247.
  39. Wurzburger R. A Case of Delayed Hepatic Injury Associated with Teriflunomide Use as Assessed for Causality Using the Updated RUCAM. Case Reports Hepatol. 2022 Jun 15;2022:6331923. doi: 10.1155/2022/6331923. PMID: 35756947; PMCID: PMC9217622.
  40. Yang H, Guo D, Xu Y, Zhu M, Yao C, Chen C, Jia W. Comparison of Different Liver Test Thresholds for Drug-Induced Liver Injury: Updated RUCAM versus Other Methods. Front Pharmacol. 2019 Jul 19;10:816. doi: 10.3389/fphar.2019.00816. PMID: 31379581; PMCID: PMC6658872.
  41. Ye L, Feng Z, Huang L, Guo C, Wu X, He L, Tan W, Wang Y, Wu X, Hu B, Li T, Yang G, Chengxian G, He Q. Causality Evaluation of Drug-Induced Liver Injury in Newborns and Children in the Intensive Care Unit Using the Updated Roussel Uclaf Causality Assessment Method. Front Pharmacol. 2021 Dec 20;12:790108. doi: 10.3389/fphar.2021.790108. PMID: 34987403; PMCID: PMC8721278.
  42. Zhang B, Jiang G, Wang L, Li X, Zhao C, Tan Q, Kang W, Feng Y, Han X, Raza HK, Mao Y. An analysis of silybin meglumine tablets in the treatment of drug-induced liver injury as assessed for causality with the updated Roussel Uclaf Causality Assessment Method using a nationwide database. Br J Clin Pharmacol. 2023 Apr;89(4):1329-1337. doi: 10.1111/bcp.15575. Epub 2022 Nov 10. PMID: 36278948.
  43. Teschke R, Danan G. Drug induced liver injury with analysis of alternative causes as confounding variables. Br J Clin Pharmacol. 2018 Jul;84(7):1467-1477. doi: 10.1111/bcp.13593. Epub 2018 May 14. PMID: 29607530; PMCID: PMC6005631.
  44. Hosack T, Damry D, Biswas S. Drug-induced liver injury: a comprehensive review. Therap Adv Gastroenterol. 2023 Mar 21;16:17562848231163410. doi: 10.1177/17562848231163410. PMID: 36968618; PMCID: PMC10031606.
  45. Saleh AK, El-Masry TA, El-Kadem AH, Ashour NA, El-Mahdy NA. Exploring drug-induced liver injury: comprehensive insights into mechanisms and management of hepatotoxic agents. Futur J Pharm Sci. 2025; 11: 38. doi: 0.1186/s43094-025-00788-5.
  46. Allison R, Guraka A, Shawa IT, Tripathi G, Moritz W, Kermanizadeh A. Drug induced liver injury - a 2023 update. J Toxicol Environ Health B Crit Rev. 2023 Nov 17;26(8):442-467. doi: 10.1080/10937404.2023.2261848. Epub 2023 Oct 19. PMID: 37786264.
  47. Teschke R. Treatment of drug-induced liver injury. In Special Issue: Liver Disease and Therapy, Guest Editor: Nahum Méndez-Sánchez. Biomedicines. 2023; 11: 15. doi: 10.3390/biomedicines11010015.
  48. Li M, Luo Q, Tao Y, Sun X, Liu C. Pharmacotherapies for Drug-Induced Liver Injury: A Current Literature Review. Front Pharmacol. 2022 Jan 5;12:806249. doi: 10.3389/fphar.2021.806249. PMID: 35069218; PMCID: PMC8766857.
  49. Niu H, Ma J, Medina-Caliz I, Robles-Diaz M, Bonilla-Toyos E, Ghabril M, Lucena MI, Alvarez-Alvarez I, Andrade RJ. Potential benefit and lack of serious risk from corticosteroids in drug-induced liver injury: An international, multicentre, propensity score-matched analysis. Aliment Pharmacol Ther. 2023 Apr;57(8):886-896. doi: 10.1111/apt.17373. Epub 2022 Dec 22. PMID: 36547393.
  50. Hu PF, Wang PQ, Chen H, Hu XF, Xie QP, Shi J, Lin L, Xie WF. Beneficial effect of corticosteroids for patients with severe drug-induced liver injury. J Dig Dis. 2016 Sep;17(9):618-627. doi: 10.1111/1751-2980.12383. PMID: 27426618.
  51. Wu H, Yan W, Liu K, Jing J, Ye W. Propensity score matching-based analysis of the effect of corticosteroids in treating severe drug-induced liver injury. Clin Res Hepatol Gastroenterol. 2024 Nov;48(9):102472. doi: 10.1016/j.clinre.2024.102472. Epub 2024 Sep 25. PMID: 39332764.
  52. Qi X, Liu X. Introductory chapter: Glucocorticoids for acute severe drug-induced liver injury. current controversy. In: Qi X, Liu X, editors. Understanding Hepatotoxicity – Causes, Symptoms and Prevention. IntechOpen. 2025. doi: 10.5772/intechopen.1010605.
  53. Teschke R, Danan G. Idiosyncratic Drug Induced Liver Injury, Cytochrome P450, Metabolic Risk Factors and Lipophilicity: Highlights and Controversies. Int J Mol Sci. 2021 Mar 26;22(7):3441. doi: 10.3390/ijms22073441. PMID: 33810530; PMCID: PMC8037096.
  54. Tasnim F, Huang X, Lee CZW, Ginhoux F, Yu H. Recent Advances in Models of Immune-Mediated Drug-Induced Liver Injury. Front Toxicol. 2021 Apr 27;3:605392. doi: 10.3389/ftox.2021.605392. PMID: 35295156; PMCID: PMC8915912.
  55. Liaskou E, Wilson DV, Oo YH. Innate immune cells in liver inflammation. Mediators Inflamm. 2012;2012:949157. doi: 10.1155/2012/949157. Epub 2012 Aug 9. PMID: 22933833; PMCID: PMC3425885.
  56. Waddington J C, Meng X, Naisbitt DJ, Park BK. Immune drug-induced liver disease and drugs. Curr Opin Toxicol. 2018; 10: 46–53. doi: 10.1016/j.cotox.2017.12.006.
  57. Mak A, Uetrecht J. Immune mechanisms of idiosyncratic drug-induced liver injury. J Clin Transl Res. 2017 Feb 12;3(1):145-156. PMID: 30873473; PMCID: PMC6410666.
  58. Steuerwald NM, Foureau DM, Norton HJ, Zhou J, Parsons JC, Chalasani N, Fontana RJ, Watkins PB, Lee WM, Reddy KR, Stolz A, Talwalkar J, Davern T, Saha D, Bell LN, Barnhart H, Gu J, Serrano J, Bonkovsky HL. Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance. PLoS One. 2013 Dec 27;8(12):e81974. doi: 10.1371/journal.pone.0081974. PMID: 24386086; PMCID: PMC3873930.
  59. Li J, Zhu X, Liu F, Cai P, Sanders C, Lee WM, Uetrecht J. Cytokine and autoantibody patterns in acute liver failure. J Immunotoxicol. 2010 Jul-Sep;7(3):157-64. doi: 10.3109/15476910903501748. PMID: 20039781; PMCID: PMC4937798.
  60. Liu MN, Au M, Bishara M, Worland T, Con D, Chew S, McNiece A, Gronbaek H, Sluka P, Nicoll AJ. Serum interleukin-4 is elevated in clinical drug-induced liver injury. Scand J Gastroenterol. 2023 Jul-Dec;58(12):1499-1504. doi: 10.1080/00365521.2023.2237154. Epub 2023 Jul 18. PMID: 37464727.
  61. Teschke R, Eickhoff A. Acute liver failure due to assumed drug induced liver injury but lack of any validated diagnostic causality algorithm: evidence by 36 cohort reports with 21,709 cases. In Special Issue: Diagnostic requirements including algorithms and biomarkers in liver transplantation, Guest Editor Rolf Teschke. OBM Transplantation. 2025; 9: 234. doi:10.21926/obm.transplant.2501234.
  62. Martínez-Casas OY, Díaz-Ramírez GS, Marín-Zuluaga JI, Muñoz-Maya O, Santos O, Donado-Gómez JH, Restrepo-Gutiérrez JC. Differential characteristics in drug-induced autoimmune hepatitis. JGH Open. 2018 May 24;2(3):97-104. doi: 10.1002/jgh3.12054. PMID: 30483571; PMCID: PMC6207017.
  63. Chung Y, Morrison M, Zen Y, Heneghan MA. Defining characteristics and long-term prognosis of drug-induced autoimmune-like hepatitis: A retrospective cohort study. United European Gastroenterol J. 2024 Feb;12(1):66-75. doi: 10.1002/ueg2.12499. Epub 2023 Dec 2. PMID: 38041550; PMCID: PMC10859714.
  64. Weber S, Benesic A, Rotter I, Gerbes AL. Early ALT response to corticosteroid treatment distinguishes idiosyncratic drug-induced liver injury from autoimmune hepatitis. Liver Int. 2019 Oct;39(10):1906-1917. doi: 10.1111/liv.14195. Epub 2019 Aug 5. PMID: 31319011.
  65. García-Cortés M, Ortega-Alonso A, Matilla-Cabello G, Medina-Cáliz I, Castiella A, Conde I, Bonilla-Toyos E, Pinazo-Bandera J, Hernández N, Tagle M, Nunes V, Parana R, Bessone F, Kaplowitz N, Lucena MI, Alvarez-Alvarez I, Robles-Díaz M, Andrade RJ. Clinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registries. Liver Int. 2023 Aug;43(8):1749-1760. doi: 10.1111/liv.15623. Epub 2023 Jun 3. PMID: 37269163.
  66. Licata A, Maida M, Cabibi D, Butera G, Macaluso FS, Alessi N, Caruso C, Craxì A, Almasio PL. Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study. Dig Liver Dis. 2014 Dec;46(12):1116-20. doi: 10.1016/j.dld.2014.08.040. Epub 2014 Sep 16. PMID: 25224696.
  67. Yeong TT, Lim KH, Goubet S, Parnell N, Verma S. Natural history and outcomes in drug-induced autoimmune hepatitis. Hepatol Res. 2016 Mar;46(3):E79-88. doi: 10.1111/hepr.12532. Epub 2015 May 25. PMID: 25943838.
  68. Tan CK, Ho D, Wang LM, Kumar R. Drug-induced autoimmune hepatitis: A minireview. World J Gastroenterol. 2022 Jun 28;28(24):2654-2666. doi: 10.3748/wjg.v28.i24.2654. PMID: 35979160; PMCID: PMC9260871.
  69. Tse J, Natla S, Mekala R, Crumm I, Olken MH. Atorvastatin-Induced Autoimmune Hepatitis: A Case Report. Cureus. 2023 Oct 27;15(10):e47807. doi: 10.7759/cureus.47807. PMID: 38021877; PMCID: PMC10679798.
  70. Hassoun J, Goossens N, Restellini S, Ramer L, Ongaro M, Giostra E, Hadengue A, Rubbia-Brandt L, Spahr L. Discontinuation of immunosuppression in patients with immune-mediated drug-induced liver injury or idiopathic autoimmune hepatitis: A case-control study. JGH Open. 2023 Jan 11;7(2):135-140. doi: 10.1002/jgh3.12862. PMID: 36852147; PMCID: PMC9958343.
  71. Valgeirsson KB, Hreinsson JP, Björnsson ES. Increased incidence of autoimmune hepatitis is associated with wider use of biological drugs. Liver Int. 2019 Dec;39(12):2341-2349. doi: 10.1111/liv.14224. Epub 2019 Aug 30. PMID: 31436903.
  72. Björnsson ES, Bergmann O, Jonasson JG, Grondal G, Gudbjornsson B, Olafsson S. Drug-Induced Autoimmune Hepatitis: Response to Corticosteroids and Lack of Relapse After Cessation of Steroids. Clin Gastroenterol Hepatol. 2017 Oct;15(10):1635-1636. doi: 10.1016/j.cgh.2017.05.027. Epub 2017 May 20. PMID: 28535988.
  73. Alqrinawi SH, Akbar N, AlFaddag H, Akbar S, Akbar L, Butt SA, Aljawad M. Menotrophin Induced Autoimmune Hepatitis. Case Rep Gastrointest Med. 2019 Sep 2;2019:7343805. doi: 10.1155/2019/7343805. PMID: 31565446; PMCID: PMC6745122.
  74. Ghabril M, Bonkovsky HL, Kum C, Davern T, Hayashi PH, Kleiner DE, Serrano J, Rochon J, Fontana RJ, Bonacini M; US Drug-Induced Liver Injury Network. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol. 2013 May;11(5):558-564.e3. doi: 10.1016/j.cgh.2012.12.025. Epub 2013 Jan 17. PMID: 23333219; PMCID: PMC3865702.
  75. Rodrigues S, Lopes S, Magro F, Cardoso H, Horta e Vale AM, Marques M, Mariz E, Bernardes M, Lopes J, Carneiro F, Macedo G. Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: A single center report of 8 cases. World J Gastroenterol. 2015 Jun 28;21(24):7584-8. doi: 10.3748/wjg.v21.i24.7584. PMID: 26140007; PMCID: PMC4481456.
  76. Khan AA, Ahmed S, Mohammed A, Elzouki AY. Autoimmune-like Drug-induced Liver Injury Caused by Atorvastatin and Demonstration of the Safety Profile of Pravastatin: A Case Report and Literature Review. Cureus. 2020 Mar 17;12(3):e7299. doi: 10.7759/cureus.7299. PMID: 32313740; PMCID: PMC7163344.
  77. Björnsson E, Talwalkar J, Treeprasertsuk S, Kamath PS, Takahashi N, Sanderson S, Neuhauser M, Lindor K. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology. 2010 Jun;51(6):2040-8. doi: 10.1002/hep.23588. PMID: 20512992.
  78. de Boer YS, Kosinski AS, Urban TJ, Zhao Z, Long N, Chalasani N, Kleiner DE, Hoofnagle JH; Drug-Induced Liver Injury Network. Features of Autoimmune Hepatitis in Patients With Drug-induced Liver Injury. Clin Gastroenterol Hepatol. 2017 Jan;15(1):103-112.e2. doi: 10.1016/j.cgh.2016.05.043. Epub 2016 Jun 14. PMID: 27311619; PMCID: PMC5370577.
  79. Björnsson HK, Gudbjornsson B, Björnsson ES. Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment. J Hepatol. 2022 Jan;76(1):86-92. doi: 10.1016/j.jhep.2021.08.024. Epub 2021 Sep 3. PMID: 34487751.
  80. Harmon EG, McConnie R, Kesavan A. Minocycline-Induced Autoimmune Hepatitis: A Rare But Important Cause of Drug-Induced Autoimmune Hepatitis. Pediatr Gastroenterol Hepatol Nutr. 2018 Oct;21(4):347-350. doi: 10.5223/pghn.2018.21.4.347. Epub 2018 Oct 10. PMID: 30345250; PMCID: PMC6182477.
  81. Fortunati F, Froidure A, Baldin P, Horsmans Y, Lanthier N, Dahlqvist G, Delire B. Pirfenidone-induced liver injury, a case report of a rare idiosyncratic reaction. Ther Adv Drug Saf. 2024 Sep 14;15:20420986241270866. doi: 10.1177/20420986241270866. PMID: 39286238; PMCID: PMC11403680.
  82. Qu LM, Wang SH, Yang K, Brigstock DR, Sun L, Gao RP. CD4+Foxp3+CD25+/- Tregs characterize liver tissue specimens of patients suffering from drug-induced autoimmune hepatitis: A clinical-pathological study. Hepatobiliary Pancreat Dis Int. 2018 Apr;17(2):133-139. doi: 10.1016/j.hbpd.2018.02.004. Epub 2018 Feb 19. PMID: 29551296.
  83. Heneghan MA, Lohse AW. Update in clinical science: Autoimmune hepatitis. J Hepatol. 2025 May;82(5):926-937. doi: 10.1016/j.jhep.2024.12.041. Epub 2025 Jan 27. PMID: 39864459.
  84. Sirbe C, Simu G, Szabo I, Grama A, Pop TL. Pathogenesis of Autoimmune Hepatitis-Cellular and Molecular Mechanisms. Int J Mol Sci. 2021 Dec 17;22(24):13578. doi: 10.3390/ijms222413578. PMID: 34948375; PMCID: PMC8703580.
  85. Fan JH, Liu GF, Lv XD, Zeng RZ, Zhan LL, Lv XP. Pathogenesis of autoimmune hepatitis. World J Hepatol. 2021 Aug 27;13(8):879-886. doi: 10.4254/wjh.v13.i8.879. PMID: 34552694; PMCID: PMC8422914.
  86. Thomas D, Wu TY, Cottagiri M, Nyandjo M, Njoku DB. Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms. J Vis Exp. 2020 May 29;(159). doi: 10.3791/59174. PMID: 32538903.
  87. Harmon EG, McConnie R, Kesavan A. Minocycline-Induced Autoimmune Hepatitis: A Rare But Important Cause of Drug-Induced Autoimmune Hepatitis. Pediatr Gastroenterol Hepatol Nutr. 2018 Oct;21(4):347-350. doi: 10.5223/pghn.2018.21.4.347. Epub 2018 Oct 10. PMID: 30345250; PMCID: PMC6182477.
  88. Sakakibara M, Ohkawa K, Nawa T, Abe Y, Kusakabe A, Imai T, Katayama K. Two-step progression of varenicline-induced autoimmune hepatitis. Clin J Gastroenterol. 2018 Jun;11(3):184-187. doi: 10.1007/s12328-018-0824-x. Epub 2018 Jan 30. PMID: 29383494.
  89. Teschke R. Drug-Induced Autoimmune Hepatitis by Varenicline and Infliximab as a Continuous Disease Spectrum with Two Different Flares: Acute Liver Injury Followed by Hepatic Autoimmunity. Int J Mol Sci. 2025 Sep 30;26(19):9574. doi: 10.3390/ijms26199574. PMID: 41096839; PMCID: PMC12525297.
  90. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Varenicline. [Updated 2020 Jul 22]. Accessed 29 September 2025. https://www.ncbi.nlm.nih.gov/books/NBK548100/
  91. Obach RS, Reed-Hagen AE, Krueger SS, Obach BJ, O'Connell TN, Zandi KS, Miller S, Coe JW. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos. 2006 Jan;34(1):121-30. doi: 10.1124/dmd.105.006767. Epub 2005 Oct 12. PMID: 16221753.
  92. Turnheim K, Krivanek P, Oberbauer R. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. Br J Clin Pharmacol. 1999 Oct;48(4):501-9. doi: 10.1046/j.1365-2125.1999.00041.x. PMID: 10583019; PMCID: PMC2014375.
  93. Hautekeete ML, Horsmans Y, Van Waeyenberge C, Demanet C, Henrion J, Verbist L, Brenard R, Sempoux C, Michielsen PP, Yap PS, Rahier J, Geubel AP. HLA association of amoxicillin-clavulanate--induced hepatitis. Gastroenterology. 1999 Nov;117(5):1181-6. doi: 10.1016/s0016-5085(99)70404-x. PMID: 10535882.
  94. Johansson I, Ingelman-Sundberg M. Genetic polymorphism and toxicology--with emphasis on cytochrome p450. Toxicol Sci. 2011 Mar;120(1):1-13. doi: 10.1093/toxsci/kfq374. Epub 2010 Dec 13. PMID: 21149643.
  95. Myers AL, Kawedia JD, Champlin RE, Kramer MA, Nieto Y, Ghose R, Andersson BS. Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. Expert Opin Drug Metab Toxicol. 2017 Sep;13(9):901-923. doi: 10.1080/17425255.2017.1360277. Epub 2017 Aug 17. PMID: 28766962; PMCID: PMC5584057.
  96. Amano T, Fukami T, Ogiso T, Hirose D, Jones JP, Taniguchi T, Nakajima M. Identification of enzymes responsible for dantrolene metabolism in the human liver: A clue to uncover the cause of liver injury. Biochem Pharmacol. 2018 May;151:69-78. doi: 10.1016/j.bcp.2018.03.002. Epub 2018 Mar 6. PMID: 29522712.
  97. Andrade C, Freitas L, Oliveira V. Twenty-six years of HIV science: an overview of anti-
  98. HIV drugs metabolism. Braz J Pharmaceut Sci. 2011; 47: 209-230. doi: 10.1590/S1984-82502011000200003.
  99. Landowski CP, Song X, Lorenzi PL, Hilfinger JM, Amidon GL. Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism. Pharm Res. 2005 Sep;22(9):1510-8. doi: 10.1007/s11095-005-6156-9. Epub 2005 Aug 24. PMID: 16132363.
  100. Talseth T. Kinetics of hydralazine elimination. Clin Pharmacol Ther. 1977 Jun;21(6):715-20. doi: 10.1002/cpt1977216715. PMID: 862310.
  101. LiverTox. Clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012. infliximab. Last updated 10 February 2017. https//www.nbci. nim.nih.gov/books/. Accessed 25 September 2025.
  102. Okuno H, Kitao Y, Takasu M, Kano H, Kunieda K, Seki T, Shiozaki Y, Sameshima Y. Depression of drug metabolizing activity in the human liver by interferon-alpha. Eur J Clin Pharmacol. 1990;39(4):365-7. doi: 10.1007/BF00315411. PMID: 2076719.
  103. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet. 1997 Mar;32(3):210-58. doi: 10.2165/00003088-199732030-00004. PMID: 9084960.
  104. Kim JH, Choi WG, Lee S, Lee HS. Revisiting the Metabolism and Bioactivation of Ketoconazole in Human and Mouse Using Liquid Chromatography-Mass Spectrometry-Based Metabolomics. Int J Mol Sci. 2017 Mar 13;18(3):621. doi: 10.3390/ijms18030621. PMID: 28335386; PMCID: PMC5372636.
  105. Donehower RC. Metabolic conversion of methotrexate in man. Recent Results Cancer Res. 1980;74:37-41. doi: 10.1007/978-3-642-81488-4_5. PMID: 7444148.
  106. Nelis HJ, De Leenheer AP. Metabolism of minocycline in humans. Drug Metab Dispos. 1982 Mar-Apr;10(2):142-6. PMID: 6124399.
  107. Wang Y, Gray JP, Mishin V, Heck DE, Laskin DL, Laskin JD. Role of cytochrome P450 reductase in nitrofurantoin-induced redox cycling and cytotoxicity. Free Radic Biol Med. 2008 Mar 15;44(6):1169-79. doi: 10.1016/j.freeradbiomed.2007.12.013. Epub 2007 Dec 23. PMID: 18206659; PMCID: PMC5793909.
  108. Shih TY, Pai CY, Yang P, Chang WL, Wang NC, Hu OY. A novel mechanism underlies the hepatotoxicity of pyrazinamide. Antimicrob Agents Chemother. 2013 Apr;57(4):1685-90. doi: 10.1128/AAC.01866-12. Epub 2013 Jan 28. PMID: 23357778; PMCID: PMC3623344.
  109. Acocella G. Pharmacokinetics and metabolism of rifampin in humans. Rev Infect Dis. 1983 Jul-Aug;5 Suppl 3:S428-32. doi: 10.1093/clinids/5.supplement_3.s428. PMID: 6356276.
  110. Das KM, Chowdhury JR, Zapp B, Fara JW. Small bowel absorption of sulfasalazine and its hepatic metabolism in human beings, cats, and rats. Gastroenterology. 1979 Aug;77(2):280-4. PMID: 36326.
  111. Choughule KV, Barnaba C, Joswig-Jones CA, Jones JP. In vitro oxidative metabolism of 6-mercaptopurine in human liver: insights into the role of the molybdoflavoenzymes aldehyde oxidase, xanthine oxidase, and xanthine dehydrogenase. Drug Metab Dispos. 2014 Aug;42(8):1334-40. doi: 10.1124/dmd.114.058107. Epub 2014 May 13. PMID: 24824603; PMCID: PMC4109211.
  112. Sprague D, Bambha K. Drug-induced liver injury due to varenicline: a case report. BMC Gastroenterol. 2012 Jun 8;12:65. doi: 10.1186/1471-230X-12-65. PMID: 22681894; PMCID: PMC3407017.
  113. Mogensen H, Björnsson ES. Varenicline-induced acute liver injury with jaundice. Hepatology. 2015 Jun;61(6):2110-1. doi: 10.1002/hep.27809. Epub 2015 Apr 27. PMID: 25820383.
  114. Franck AJ, Sliter LR. Acute hepatic injury associated with varenicline in a patient with underlying liver disease. Ann Pharmacother. 2009 Sep;43(9):1539-43. doi: 10.1345/aph.1M131. Epub 2009 Jul 28. PMID: 19638471.
  115. Faessel HM, Obach RS, Rollema H, Ravva P, Williams KE, Burstein AH. A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clin Pharmacokinet. 2010 Dec;49(12):799-816. doi: 10.2165/11537850-000000000-00000. PMID: 21053991.
  116. Singh D, Saadabadi A. Varenicline. [Updated 2024 Oct 5]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Accessed 19 August 2025. https://www.ncbi.nlm.nih.gov/sites/books/NBK534846
  117. Klotz U, Teml A, Schwab M. Clinical pharmacokinetics and use of infliximab. Clin Pharmacokinet. 2007;46(8):645-60. doi: 10.2165/00003088-200746080-00002. PMID: 17655372.
  118. Choquette D, Faraawi R, Chow A, Rodrigues J, Bensen WJ, Nantel F. Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry. J Rheumatol. 2015 Jul;42(7):1105-11. doi: 10.3899/jrheum.140538. Epub 2015 Jun 15. PMID: 26077415.
  119. Anwar R. Infliximab pharmacokinetics: an in-depth analysis. J Pharmacokinet Exp
  120. Ther. 2024; 8: 275. doi: 10.4172/jpet.1000275
  121. Mc Gettigan N, Afridi AS, Harkin G, Lardner C, Patchett S, Cheriyan D, Harewood G, Boland K, O'Toole A. The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease. Int J Colorectal Dis. 2021 Jun;36(6):1231-1241. doi: 10.1007/s00384-021-03855-4. Epub 2021 Jan 29. PMID: 33515082.
  122. Wadhwa M, Cludts I, Atkinson E, Rigsby P. The first WHO reference panel for Infliximab anti-drug antibodies: a step towards harmonizing therapeutic drug monitoring. Front Immunol. 2025 Mar 20;16:1550655. doi: 10.3389/fimmu.2025.1550655. PMID: 40181987; PMCID: PMC11965635.
  123. Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, Pavelka K, Mahgoub E, Kotak S, Korth-Bradley J, Pedersen R, Mele L, Shen Q, Vlahos B. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS One. 2017 Apr 27;12(4):e0175207. doi: 10.1371/journal.pone.0175207. Erratum in: PLoS One. 2017 Jun 5;12(6):e0179308. doi: 10.1371/journal.pone.0179308. PMID: 28448562; PMCID: PMC5407581.
  124. Meunier L, Larrey D. Drug-Induced Liver Injury: Biomarkers, Requirements, Candidates, and Validation. Front Pharmacol. 2019 Dec 11;10:1482. doi: 10.3389/fphar.2019.01482. PMID: 31920666; PMCID: PMC6917655.
  125. Obermayer-Straub P, Strassburg CP, Manns MP. Target proteins in human autoimmunity: cytochromes P450 and UDP- glucuronosyltransferases. Can J Gastroenterol. 2000 May;14(5):429-39. doi: 10.1155/2000/910107. PMID: 10851284.
  126. Metushi IG, Sanders C; Acute Liver Study Group; Lee WM, Uetrecht J. Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure. Hepatology. 2014 Mar;59(3):1084-93. doi: 10.1002/hep.26564. Epub 2014 Jan 27. PMID: 23775837; PMCID: PMC4940023.
  127. Nicoll A, Moore D, Njoku D, Hockey B. Repeated exposure to modern volatile anaesthetics may cause chronic hepatitis as well as acute liver injury. BMJ Case Rep. 2012 Nov 6;2012:bcr2012006543. doi: 10.1136/bcr-2012-006543. PMID: 23131606; PMCID: PMC3666850.
  128. Jee A, Sernoskie SC, Uetrecht J. Idiosyncratic Drug-Induced Liver Injury: Mechanistic and Clinical Challenges. Int J Mol Sci. 2021 Mar 14;22(6):2954. doi: 10.3390/ijms22062954. PMID: 33799477; PMCID: PMC7998339.
  129. Njoku DB, Greenberg RS, Bourdi M, Borkowf CB, Dake EM, Martin JL, Pohl LR. Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists. Anesth Analg. 2002 Feb;94(2):243-9, table of contents. doi: 10.1097/00000539-200202000-00003. PMID: 11812677.
  130. Njoku DB, Mellerson JL, Talor MV, Kerr DR, Faraday NR, Outschoorn I, Rose NR. Role of CYP2E1 immunoglobulin G4 subclass antibodies and complement in pathogenesis of idiosyncratic drug-induced hepatitis. Clin Vaccine Immunol. 2006 Feb;13(2):258-65. doi: 10.1128/CVI.13.2.258-265.2006. PMID: 16467335; PMCID: PMC1391926.
  131. Bourdi M, Chen W, Peter RM, Martin JL, Buters JT, Nelson SD, Pohl LR. Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. Chem Res Toxicol. 1996 Oct-Nov;9(7):1159-66. doi: 10.1021/tx960083q. PMID: 8902272.
  132. Kenna JG, Neuberger J, Williams R. Identification by immunoblotting of three halothane-induced liver microsomal polypeptide antigens recognized by antibodies in sera from patients with halothane-associated hepatitis. J Pharmacol Exp Ther. 1987 Aug;242(2):733-40. PMID: 3302210.
  133. Cheron C, Hoet P, Renard N, Vanderweerden G, Miscu C, Komuta M, Laterre PF, Hantson P. Fulminant Hepatic Failure in the Course of an Outpatient Anesthetic Procedure: Sevoflurane among Other High-Risk Factors. Case Rep Anesthesiol. 2020 Jun 29;2020:5124098. doi: 10.1155/2020/5124098. PMID: 32685214; PMCID: PMC7341414.
  134. Kharasch ED. Biotransformation of sevoflurane. Anesth Analg. 1995 Dec;81(6 Suppl):S27-38. doi: 10.1097/00000539-199512001-00005. PMID: 7486145.
  135. Wandel C, Neff S, Keppler G, Böhrer H, Stockinger K, Wilkinson GR, Wood M, Martin E. The relationship between cytochrome P4502E1 activity and plasma fluoride levels after sevoflurane anesthesia in humans. Anesth Analg. 1997 Oct;85(4):924-30. doi: 10.1097/00000539-199710000-00038. PMID: 9322481.
  136. Teschke R, Danan G. Human Leucocyte Antigen Genetics in Idiosyncratic Drug-Induced Liver Injury with Evidence Based on the Roussel Uclaf Causality Assessment Method. Medicines (Basel). 2024 Apr 11;11(4):9. doi: 10.3390/medicines11040009. PMID: 38667507; PMCID: PMC11052120.
  137. Nicoletti P, Aithal GP, Chamberlain TC, Coulthard S, Alshabeeb M, Grove JI, Andrade RJ, Bjornsson E, Dillon JF, Hallberg P, Lucena MI, Maitland-van der Zee AH, Martin JH, Molokhia M, Pirmohamed M, Wadelius M, Shen Y, Nelson MR, Daly AK; International Drug-Induced Liver Injury Consortium (iDILIC). Drug-Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. Clin Pharmacol Ther. 2019 Jul;106(1):245-253. doi: 10.1002/cpt.1375. Epub 2019 Mar 19. PMID: 30661239.
  138. Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, Day CP, Ruiz-Cabello F, Donaldson PT, Stephens C, Pirmohamed M, Romero-Gomez M, Navarro JM, Fontana RJ, Miller M, Groome M, Bondon-Guitton E, Conforti A, Stricker BH, Carvajal A, Ibanez L, Yue QY, Eichelbaum M, Floratos A, Pe'er I, Daly MJ, Goldstein DB, Dillon JF, Nelson MR, Watkins PB, Daly AK; Spanish DILI Registry; EUDRAGENE; DILIN; DILIGEN; International SAEC. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology. 2011 Jul;141(1):338-47. doi: 10.1053/j.gastro.2011.04.001. Epub 2011 Apr 12. PMID: 21570397; PMCID: PMC3129430.
  139. Stephens C, López-Nevot MÁ, Ruiz-Cabello F, Ulzurrun E, Soriano G, Romero-Gómez M, Moreno-Casares A, Lucena MI, Andrade RJ. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One. 2013 Jul 9;8(7):e68111. doi: 10.1371/journal.pone.0068111. Erratum in: PLoS One. 2014;9(10):e112165. PMID: 23874514; PMCID: PMC3706603.
  140. O'Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RN, Mills PR. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut. 2000 Nov;47(5):717-20. doi: 10.1136/gut.47.5.717. PMID: 11034591; PMCID: PMC1728095.
  141. Petros Z, Kishikawa J, Makonnen E, Yimer G, Habtewold A, Aklillu E. HLA-B*57 Allele Is Associated with Concomitant Anti-tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians. Front Pharmacol. 2017 Feb 27;8:90. doi: 10.3389/fphar.2017.00090. PMID: 28289388; PMCID: PMC5326775.
  142. Nicoletti P, Barrett S, McEvoy L, Daly AK, Aithal G, Lucena MI, Andrade RJ, Wadelius M, Hallberg P, Stephens C, Bjornsson ES, Friedmann P, Kainu K, Laitinen T, Marson A, Molokhia M, Phillips E, Pichler W, Romano A, Shear N, Sills G, Tanno LK, Swale A, Floratos A, Shen Y, Nelson MR, Watkins PB, Daly MJ, Morris AP, Alfirevic A, Pirmohamed M. Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions. Clin Pharmacol Ther. 2019 Nov;106(5):1028-1036. doi: 10.1002/cpt.1493. Epub 2019 Jul 3. PMID: 31066027; PMCID: PMC7156285.
  143. Devarbhavi H, Patil M, Menon M. Association of human leukocyte antigen-B*13:01 with dapsone-induced liver injury. Br J Clin Pharmacol. 2022 Mar;88(3):1369-1372. doi: 10.1111/bcp.15054. Epub 2021 Sep 9. PMID: 34427944.
  144. Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX, Bondon-Guitton E, Hayashi PH, Bessone F, Carvajal A, Cascorbi I, Cirulli ET, Chalasani N, Conforti A, Coulthard SA, Daly MJ, Day CP, Dillon JF, Fontana RJ, Grove JI, Hallberg P, Hernández N, Ibáñez L, Kullak-Ublick GA, Laitinen T, Larrey D, Lucena MI, Maitland-van der Zee AH, Martin JH, Molokhia M, Pirmohamed M, Powell EE, Qin S, Serrano J, Stephens C, Stolz A, Wadelius M, Watkins PB, Floratos A, Shen Y, Nelson MR, Urban TJ, Daly AK; International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium. Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. Gastroenterology. 2017 Apr;152(5):1078-1089. doi: 10.1053/j.gastro.2016.12.016. Epub 2016 Dec 30. PMID: 28043905; PMCID: PMC5367948.
  145. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, Daly MJ, Goldstein DB, John S, Nelson MR, Graham J, Park BK, Dillon JF, Bernal W, Cordell HJ, Pirmohamed M, Aithal GP, Day CP; DILIGEN Study; International SAE Consortium. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet. 2009 Jul;41(7):816-9. doi: 10.1038/ng.379. Epub 2009 May 31. PMID: 19483685.
  146. Monshi MM, Faulkner L, Gibson A, Jenkins RE, Farrell J, Earnshaw CJ, Alfirevic A, Cederbrant K, Daly AK, French N, Pirmohamed M, Park BK, Naisbitt DJ. Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology. 2013 Feb;57(2):727-39. doi: 10.1002/hep.26077. PMID: 22987284.
  147. Teixeira M, Macedo S, Batista T, Martins S, Correia A, Matos LC. Flucloxacillin-Induced Hepatotoxicity - Association with HLA-B*5701. Rev Assoc Med Bras (1992). 2020 Feb 27;66(1):12-17. doi: 10.1590/1806-9282.66.1.12. PMID: 32130375.
  148. Nicoletti P, Werk AN, Sawle A, Shen Y, Urban TJ, Coulthard SA, Bjornsson ES, Cascorbi I, Floratos A, Stammschulte T, Gundert-Remy U, Nelson MR, Aithal GP, Daly AK; International Drug-induced Liver Injury Consortium. HLA-DRB1*16: 01-DQB1*05: 02 is a novel genetic risk factor for flupirtine-induced liver injury. Pharmacogenet Genomics. 2016 May;26(5):218-24. doi: 10.1097/FPC.0000000000000209. PMID: 26959717.
  149. Bruno CD, Fremd B, Church RJ, Daly AK, Aithal GP, Björnsson ES, Larrey D, Watkins PB, Chow CR. HLA associations with infliximab-induced liver injury. Pharmacogenomics J. 2020 Oct;20(5):681-686. doi: 10.1038/s41397-020-0159-0. Epub 2020 Feb 6. PMID: 32024945.
  150. Li X, Jin S, Fan Y, Fan X, Tang Z, Cai W, Yang J, Xiang X. Association of HLA-C*03:02 with methimazole-induced liver injury in Graves' disease patients. Biomed Pharmacother. 2019 Sep;117:109095. doi: 10.1016/j.biopha.2019.109095. Epub 2019 Jun 12. PMID: 31202168.
  151. Urban TJ, Nicoletti P, Chalasani N, Serrano J, Stolz A, Daly AK, Aithal GP, Dillon J, Navarro V, Odin J, Barnhart H, Ostrov D, Long N, Cirulli ET, Watkins PB, Fontana RJ; Drug-Induced Liver Injury Network (DILIN); Pharmacogenetics of Drug-Induced Liver Injury group (DILIGEN); International Serious Adverse Events Consortium (iSAEC). Minocycline hepatotoxicity: Clinical characterization and identification of HLA-B∗35:02 as a risk factor. J Hepatol. 2017 Jul;67(1):137-144. doi: 10.1016/j.jhep.2017.03.010. Epub 2017 Mar 18. PMID: 28323125; PMCID: PMC5634615.
  152. Daly AK, Bjornsson ES, Lucena MI, Andrade RJ, Aithal GP. Drug-induced liver injury due to nitrofurantoin: Similar clinical features, but different HLA risk alleles in an independent cohort. J Hepatol. 2023 May;78(5):e165-e166. doi: 10.1016/j.jhep.2022.11.022. Epub 2022 Nov 30. PMID: 36460164.
  153. Li YJ, Phillips EJ, Dellinger A, Nicoletti P, Schutte R, Li D, Ostrov DA, Fontana RJ, Watkins PB, Stolz A, Daly AK, Aithal GP, Barnhart H, Chalasani N; Drug-induced Liver Injury Network. Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprim-Sulfamethoxazole Induced Liver Injury. Hepatology. 2021 Jan;73(1):268-281. doi: 10.1002/hep.31258. PMID: 32270503; PMCID: PMC7544638.
  154. Fontana RJ, Li YJ, Phillips E, Saeed N, Barnhart H, Kleiner D, Hoofnagle J; Drug Induced Liver Injury Network. Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles. Liver Int. 2021 Aug;41(8):1884-1893. doi: 10.1111/liv.14903. Epub 2021 May 7. PMID: 33899326; PMCID: PMC8286350.
  155. Kim EY, Seol JE, Choi JH, Kim NY, Shin JG. Allopurinol-induced severe cutaneous adverse reactions: A report of three cases with the HLA-B*58:01 allele who underwent lymphocyte activation test. Transl Clin Pharmacol. 2017 Jun;25(2):63-66. doi: 10.12793/tcp.2017.25.2.63. Epub 2017 Jun 15. PMID: 32133321; PMCID: PMC7042004.
  156. Meng X, Earnshaw CJ, Tailor A, Jenkins RE, Waddington JC, Whitaker P, French NS, Naisbitt DJ, Park BK. Amoxicillin and Clavulanate Form Chemically and Immunologically Distinct Multiple Haptenic Structures in Patients. Chem Res Toxicol. 2016 Oct 17;29(10):1762-1772. doi: 10.1021/acs.chemrestox.6b00253. Epub 2016 Sep 21. PMID: 27603302.
  157. Otsuka S, Yamamoto M, Kasuya S, Ohtomo H, Yamamoto Y, Yoshida TO, Akaza T. HLA antigens in patients with unexplained hepatitis following halothane anesthesia. Acta Anaesthesiol Scand. 1985 Jul;29(5):497-501. doi: 10.1111/j.1399-6576.1985.tb02242.x. PMID: 3862324.
  158. Tangamornsuksan W, Kongkaew C, Scholfield CN, Subongkot S, Lohitnavy M. HLA-DRB1*07:01 and lapatinib-induced hepatotoxicity: a systematic review and meta-analysis. Pharmacogenomics J. 2020 Feb;20(1):47-56. doi: 10.1038/s41397-019-0092-2. Epub 2019 Aug 6. PMID: 31383939.
  159. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, Wright TM, Meyer J, Paulding CA. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010 Aug;42(8):711-4. doi: 10.1038/ng.632. Epub 2010 Jul 18. PMID: 20639878.
  160. Chalasani N, Li YJ, Dellinger A, Navarro V, Bonkovsky H, Fontana RJ, Gu J, Barnhart H, Phillips E, Lammert C, Schwantes-An TH, Nicoletti P, Kleiner DE, Hoofnagle JH; Drug Induced Liver Injury Network. Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury. J Hepatol. 2023 Feb;78(2):293-300. doi: 10.1016/j.jhep.2022.09.010. Epub 2022 Sep 22. PMID: 36152763; PMCID: PMC9852026.
  161. Xu CF, Johnson T, Wang X, Carpenter C, Graves AP, Warren L, Xue Z, King KS, Fraser DJ, Stinnett S, Briley LP, Mitrica I, Spraggs CF, Nelson MR, Tada H, du Bois A, Powles T, Kaplowitz N, Pandite LN. HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer. Clin Cancer Res. 2016 Mar 15;22(6):1371-7. doi: 10.1158/1078-0432.CCR-15-2044. Epub 2015 Nov 6. PMID: 26546620; PMCID: PMC7444994.
  162. Fontana RJ, Cirulli ET, Gu J, Kleiner D, Ostrov D, Phillips E, Schutte R, Barnhart H, Chalasani N, Watkins PB, Hoofnagle JH. The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine. J Hepatol. 2018 Dec;69(6):1317-1325. doi: 10.1016/j.jhep.2018.08.004. Epub 2018 Aug 21. PMID: 30138689; PMCID: PMC6472700.
  163. Hirata K, Takagi H, Yamamoto M, Matsumoto T, Nishiya T, Mori K, Shimizu S, Masumoto H, Okutani Y. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: a preliminary case-control study. Pharmacogenomics J. 2008 Feb;8(1):29-33. doi: 10.1038/sj.tpj.6500442. Epub 2007 Mar 6. PMID: 17339877.
  164. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, Carlsson S, Cederbrant KE, Gibson NJ, Armstrong M, Lagerström-Fermér ME, Dellsén A, Brown EM, Thornton M, Dukes C, Jenkins SC, Firth MA, Harrod GO, Pinel TH, Billing-Clason SM, Cardon LR, March RE. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008 Jun;8(3):186-95. doi: 10.1038/sj.tpj.6500458. Epub 2007 May 15. PMID: 17505501.
  165. Teschke R. Idiosyncratic Hepatocellular Drug-Induced Liver Injury by Flucloxacillin with Evidence Based on Roussel Uclaf Causality Assessment Method and HLA B*57:01 Genotype: From Metabolic CYP 3A4/3A7 to Immune Mechanisms. Biomedicines. 2024 Sep 27;12(10):2208. doi: 10.3390/biomedicines12102208. PMID: 39457521; PMCID: PMC11504411.
  166. Teschke R. Liver Injury in Immune Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Five New Classification Types. J Clin Transl Hepatol. 2025 Apr 28;13(4):339-357. doi: 10.14218/JCTH.2024.00402. Epub 2025 Jan 17. PMID: 40206276; PMCID: PMC11976437.
  167. Devarbhavi H, Raj S, Aradya VH, Rangegowda VT, Veeranna GP, Singh R, Reddy V, Patil M. Drug-induced liver injury associated with Stevens-Johnson syndrome/toxic epidermal necrolysis: Patient characteristics, causes, and outcome in 36 cases. Hepatology. 2016 Mar;63(3):993-9. doi: 10.1002/hep.28270. Epub 2015 Nov 26. PMID: 26439084.
  168. Frantz R, Huang S, Are A, Motaparthi K. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review of Diagnosis and Management. Medicina (Kaunas). 2021 Aug 28;57(9):895. doi: 10.3390/medicina57090895. PMID: 34577817; PMCID: PMC8472007.
  169. Labib A, Milroy C. Toxic Epidermal Necrolysis. [Updated 2023 May 8]. StatPearls [Internet]. Treasure Island (FL) :StatPearls Publishing; 2024-. doi: 10.3390/medicina57090895.
  170. Zimmerman D, Dang NH. Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN): Immunologic reactions. Oncologic Critical Care. Columbus, OH, USA: Springer International Publishing; 2019: 267-280. doi: 10.1007/978-3-319-74588-6_195.
  171. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010 Dec 16;5:39. doi: 10.1186/1750-1172-5-39. PMID: 21162721; PMCID: PMC3018455.
  172. Wang L, Varghese S, Bassir F, Lo YC, Ortega CA, Shah S, Blumenthal KG, Phillips EJ, Zhou L. Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review of PubMed/MEDLINE case reports from 1980 to 2020. Front Med (Lausanne). 2022 Aug 24;9:949520. doi: 10.3389/fmed.2022.949520. PMID: 36091694; PMCID: PMC9449801.
  173. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000 Aug;115(2):149-53. doi: 10.1046/j.1523-1747.2000.00061.x. PMID: 10951229.
  174. Chen CB, Wang CW, Chung WH. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the Era of Systems Medicine. Methods Mol Biol. 2022;2486:37-54. doi: 10.1007/978-1-0716-2265-0_3. PMID: 35437717.
  175. Erduran F, Adışen E, Emre S, Hayran Y, Başkan EB, Yazıcı S, Bilgiç A, Alpsoy E, Günaydın SD, Elmas L, Akyol M, Güner R, Arıca DA, Aypek Y, Ergun T, Karavelioğlu D, Yazıcı AC, Aydoğan K, Bayramgürler D, Kıran R, Erdoğan HK, Acer E, Aktaş A. Evaluation of the Factors Influencing Mortality in Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Study of 166 Patients. Dermatol Ther (Heidelb). 2024 Jun;14(6):1547-1560. doi: 10.1007/s13555-024-01180-6. Epub 2024 May 17. PMID: 38758423; PMCID: PMC11169098.
  176. Devarbhavi H, Raj S, Aradya VH, Rangegowda VT, Veeranna GP, Singh R, Reddy V, Patil M. Drug-induced liver injury associated with Stevens-Johnson syndrome/toxic epidermal necrolysis: Patient characteristics, causes, and outcome in 36 cases. Hepatology. 2016 Mar;63(3):993-9. doi: 10.1002/hep.28270. Epub 2015 Nov 26. PMID: 26439084.
  177. Zhang Z, Li S, Zhang Z, Yu K, Duan X, Long L, Zhang S, Jiang M, Liu O. Clinical Features, Risk Factors, and Prognostic Markers of Drug-Induced Liver Injury in Patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Indian J Dermatol. 2020 Jul-Aug;65(4):274-278. doi: 10.4103/ijd.IJD_217_19. PMID: 32831367; PMCID: PMC7423232.
  178. Ortega-Alonso A, Stephens C, Lucena MI, Andrade RJ. Case Characterization, Clinical Features and Risk Factors in Drug-Induced Liver Injury. Int J Mol Sci. 2016 May 12;17(5):714. doi: 10.3390/ijms17050714. PMID: 27187363; PMCID: PMC4881536.
  179. Devarbhavi H, Sridhar A, Kurien SS, Gowda V, Kothari K, Patil M, Singh R. Clinical and Liver Biochemistry Phenotypes, and Outcome in 133 Patients with Anti-seizure Drug-Induced Liver Injury. Dig Dis Sci. 2023 May;68(5):2099-2106. doi: 10.1007/s10620-022-07777-1. Epub 2022 Dec 9. PMID: 36484972.
  180. Agrawal R, Almoghrabi A, Attar BM, Gandhi S. Fluoxetine-induced Stevens-Johnson syndrome and liver injury. J Clin Pharm Ther. 2019 Feb;44(1):115-118. doi: 10.1111/jcpt.12760. Epub 2018 Oct 8. PMID: 30296343.
  181. Xiong H, Liu T, Xiao J, Wan J, Yang J, Huang G, Han Y, Liu G, Dong X. Warfarin-induced Stevens-Johnson syndrome with severe liver injury. J Int Med Res. 2021 Jul;49(7):3000605211033196. doi: 10.1177/03000605211033196. PMID: 34311601; PMCID: PMC8320577.
  182. Gronich N, Maman D, Stein N, Saliba W. Culprit Medications and Risk Factors Associated with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Population-Based Nested Case-Control Study. Am J Clin Dermatol. 2022 Mar;23(2):257-266. doi: 10.1007/s40257-021-00661-0. Epub 2022 Feb 4. PMID: 35119606; PMCID: PMC8814784.
  183. Yang SC, Hu S, Zhang SZ, Huang JW, Zhang J, Ji C, Cheng B. The Epidemiology of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in China. J Immunol Res. 2018 Feb 11;2018:4320195. doi: 10.1155/2018/4320195. Erratum in: J Immunol Res. 2018 Jun 28;2018:4154507. doi: 10.1155/2018/4154507. PMID: 29607330; PMCID: PMC5828103.
  184. Wang L, Varghese S, Bassir F, Lo YC, Ortega CA, Shah S, Blumenthal KG, Phillips EJ, Zhou L. Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review of PubMed/MEDLINE case reports from 1980 to 2020. Front Med (Lausanne). 2022 Aug 24;9:949520. doi: 10.3389/fmed.2022.949520. PMID: 36091694; PMCID: PMC9449801.
  185. Lim JH, Kim HS, Kim HO, Park YM. Stevens-Johnson syndrome following occupational exposure to carbamate insecticide. J Dermatol. 2010 Feb;37(2):182-4. doi: 10.1111/j.1346-8138.2009.00784.x. PMID: 20175856.
  186. Chung WH, Shih SR, Chang CF, Lin TY, Huang YC, Chang SC, Liu MT, Ko YS, Deng MC, Liau YL, Lin LH, Chen TH, Yang CH, Ho HC, Lin JW, Lu CW, Lu CF, Hung SI. Clinicopathologic analysis of coxsackievirus a6 new variant induced widespread mucocutaneous bullous reactions mimicking severe cutaneous adverse reactions. J Infect Dis. 2013 Dec 15;208(12):1968-78. doi: 10.1093/infdis/jit383. Epub 2013 Jul 31. PMID: 23904296.
  187. De Guido C, Calderaro A, Ruozi MB, Maffini V, Varini M, Lapetina I, Rubini M, Montecchini S, Caffarelli C, Dodi I. An unusual cause of Steven-Johnson Syndrome. Acta Biomed. 2020 Mar 19;91(1):128-131. doi: 10.23750/abm.v91i1.7692. PMID: 32191666; PMCID: PMC7569570.
  188. Voltan A, Azzena B. A case of toxic epidermal necrolysis (ten) with severe chronic ocular complications in a healthy 46-year-old woman. Ann Burns Fire Disasters. 2010 Jun 30;23(2):81-7. PMID: 21991203; PMCID: PMC3188249.
  189. Kim HI, Kim SW, Park GY, Kwon EG, Kim HH, Jeong JY, Chang HH, Lee JM, Kim NS. Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients. Korean J Intern Med. 2012 Jun;27(2):203-10. doi: 10.3904/kjim.2012.27.2.203. Epub 2012 May 31. PMID: 22707893; PMCID: PMC3372805.
  190. Zang X, Chen S, Zhang L, Zhai Y. Toxic epidermal necrolysis in hepatitis A infection with acute-on-chronic liver failure: Case report and literature review. Front Med (Lausanne). 2022 Sep 23;9:964062. doi: 10.3389/fmed.2022.964062. PMID: 36213642; PMCID: PMC9537471.
  191. McKinley BJ, Allen ME, Michels N. Photodistributed Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and proposal for a new diagnostic classification. Eur J Med Res. 2023 Jun 12;28(1):188. doi: 10.1186/s40001-023-01142-2. PMID: 37303053; PMCID: PMC10259004.
  192. Wolff K, Johnson R, Saavedra AP, Roh EK. The acutely ill and hospitalized patient. In: Fitzpatrick’s color atlas and synopsis of clinical dermatology, 8e. New York; 2012. Accessed 23 September 2025. http://accessmedicine.mhmedical.com/content.aspx?bookid=2043&sectionid=154897923.
  193. Diphoorn J, Cazzaniga S, Gamba C, Schroeder J, Citterio A, Rivolta AL, Vighi GD, Naldi L; REACT-Lombardia study group. Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry. Pharmacoepidemiol Drug Saf. 2016 Feb;25(2):196-203. doi: 10.1002/pds.3937. Epub 2015 Dec 21. PMID: 26687641.
  194. Bang D, Shah T, Thakker D, Shah Y, Raval AD. Drug-induced Stevens-Johnson syndrome: case series from tertiary care centre in Gujarat. Pharmacoepidemiol Drug Saf. 2012 Apr;21(4):384-95. doi: 10.1002/pds.3212. Epub 2012 Feb 28. PMID: 22374707.
  195. De Guido C, Calderaro A, Ruozi MB, Maffini V, Varini M, Lapetina I, Rubini M, Montecchini S, Caffarelli C, Dodi I. An unusual cause of Steven-Johnson Syndrome. Acta Biomed. 2020 Mar 19;91(1):128-131. doi: 10.23750/abm.v91i1.7692. PMID: 32191666; PMCID: PMC7569570.
  196. Nozaki Y, Fujita H, Okada R, Kou K, Aihara M. Non-drug-induced Stevens-Johnson syndrome successfully treated with high-dose i.v. immunoglobulin. J Dermatol. 2015 Apr;42(4):439-40. doi: 10.1111/1346-8138.12819. Epub 2015 Mar 7. PMID: 25753003.
  197. Shanbhag SS, Chodosh J, Fathy C, Goverman J, Mitchell C, Saeed HN. Multidisciplinary care in Stevens-Johnson syndrome. Ther Adv Chronic Dis. 2020 Apr 28;11:2040622319894469. doi: 10.1177/2040622319894469. PMID: 32523661; PMCID: PMC7236394.
  198. Cheung CMT, Chang MM, Li JJX, Chan AWS. Stevens-Johnson syndrome and toxic epidermal necrolysis in Hong Kong. Hong Kong Med J. 2024 Apr;30(2):102-109. doi: 10.12809/hkmj2210131. Epub 2024 Mar 26. PMID: 38531617.
  199. Hasegawa A, Abe R. Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. F1000Res. 2020 Jun 16;9:F1000 Faculty Rev-612. doi: 10.12688/f1000research.24748.1. PMID: 32595945; PMCID: PMC7308994.
  200. Justice J, Mukherjee E, Martin-Pozo M, Phillips E. Updates in the pathogenesis of SJS/TEN. Allergol Int. 2025 Jul;74(3):361-371. doi: 10.1016/j.alit.2025.05.002. Epub 2025 Jun 4. PMID: 40473510; PMCID: PMC12256649.
  201. Yao LM, Su X, Liu LL, Qi YN, Wei B, Ma R, Du XQ. Recent developments in the research of Stevens-Johnson syndrome and toxic epidermal necrolysis: pathogenesis, diagnosis and treatment. Eur J Med Res. 2025 Jun 5;30(1):453. doi: 10.1186/s40001-025-02664-7. PMID: 40474234; PMCID: PMC12139062.
  202. Stewart TJ, Farrell J, Frew JW. A systematic review of case-control studies of cytokines in blister fluid and skin tissue of patients with Stevens Johnson syndrome and toxic epidermal necrolysis. Australas J Dermatol. 2024 Sep;65(6):491-504. doi: 10.1111/ajd.14329. Epub 2024 Jun 3. PMID: 38831709.
  203. Redondo P, Vicente J, España A, Subira ML, De Felipe I, Quintanilla E. Photo-induced toxic epidermal necrolysis caused by clobazam. Br J Dermatol. 1996 Dec;135(6):999-1002. doi: 10.1046/j.1365-2133.1996.d01-1111.x. PMID: 8977728.
  204. Ortel B, Sivayathorn A, Hönigsmann H. An unusual combination of phototoxicity and Stevens-Johnson syndrome due to antimalarial therapy. Dermatologica. 1989;178(1):39-42. doi: 10.1159/000248385. PMID: 2917679.
  205. Suárez Moro R, Trapiella Martínez L, Avanzas González E, Salas Puig J, Fernández Fernández C. Síndrome de Stevens-Johnson secundario a carbamazepina mediado por fotosensibilidad [Stevens-Johnson syndrome secondary to carbamazepine mediated by photosensitivity]. An Med Interna. 2000 Feb;17(2):105-6. Spanish. PMID: 10829471.
  206. Borrás-Blasco J, Navarro-Ruiz A, Matarredona J, Devesa P, Montesinos-Ros A, González-Delgado M. Photo-induced Stevens-Johnson syndrome due to sulfasalazine therapy. Ann Pharmacother. 2003 Sep;37(9):1241-3. doi: 10.1345/aph.1C271. PMID: 12921507.
  207. Mansur AT, Aydingöz IA. A case of toxic epidermal necrolysis with lesions mostly on sun-exposed skin. Photodermatol Photoimmunol Photomed. 2005 Apr;21(2):100-2. doi: 10.1111/j.1600-0781.2005.00149.x. PMID: 15752129.
  208. Callaly EL, FitzGerald O, Rogers S. Hydroxychloroquine-associated, photo-induced toxic epidermal necrolysis. Clin Exp Dermatol. 2008 Aug;33(5):572-4. doi: 10.1111/j.1365-2230.2008.02704.x. Epub 2008 May 12. PMID: 18477009.
  209. Huang HT, Chang CL, Tzeng DS. Toxic epidermal necrolysis after sun-exposure probably due to lamotrigine and chlorpromazine. Asian J Psychiatr. 2010 Dec;3(4):240-2. doi: 10.1016/j.ajp.2010.09.002. Epub 2010 Oct 16. PMID: 23050897.
  210. Gatson NT, Travers JB, Al-Hassani M, Warren SJ, Hyatt AM, Travers JB. Progression of toxic epidermal necrolysis after tanning bed exposure. Arch Dermatol. 2011 Jun;147(6):719-23. doi: 10.1001/archdermatol.2011.13. Epub 2011 Feb 21. PMID: 21339416; PMCID: PMC3119720.
  211. Moghaddam S, Connolly D. Photo-induced Stevens-Johnson syndrome. J Am Acad Dermatol. 2014 Sep;71(3):e82-3. doi: 10.1016/j.jaad.2014.02.033. PMID: 25128136.
  212. Eloranta K, Karakorpi H, Jeskanen L, Kluger N. Photo-distributed Stevens-Johnson syndrome associated with oral itraconazole. Int J Dermatol. 2016 Sep;55(9):e508-10. doi: 10.1111/ijd.13278. Epub 2016 Mar 29. PMID: 27028785.
  213. Dean J, Biswas N, Robertson I. Photodistributed Stevens-Johnson syndrome associated with lamotrigine. Australas J Dermatol 2018; 59: 32–129.
  214. Russomanno K, DiLorenzo A, Horeczko J, Deng M, Cardis M, Petronic-Rosic V, Johnson LS, Pasieka HB. Photodistributed toxic epidermal necrolysis in association with lamotrigine and tanning bed exposure. JAAD Case Rep. 2021 Jun 2;14:68-71. doi: 10.1016/j.jdcr.2021.05.015. PMID: 34277913; PMCID: PMC8263525.
  215. Ogiji ED, Aboheimed N, Ross K, Voller C, Siner R, Jensen RL, Jolly CE, Carr DF. Greater mechanistic understanding of the cutaneous pathogenesis of Stevens-Johnson syndrome/toxic epidermal necrolysis can shed light on novel therapeutic strategies: a comprehensive review. Curr Opin Allergy Clin Immunol. 2024 Aug 1;24(4):218-227. doi: 10.1097/ACI.0000000000000993. Epub 2024 May 17. PMID: 38753537; PMCID: PMC11213502.
  216. Oakley AM, Krishnamurthy K. Stevens-Johnson Syndrome. 2023 Apr 10. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024.
  217. Ueta M. Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis With Severe Ocular Complications. Front Med (Lausanne). 2021 Nov 17;8:651247. doi: 10.3389/fmed.2021.651247. PMID: 34869401; PMCID: PMC8635481.
  218. Saito Y, Abe R. New insights into the diagnosis and management of Stevens-Johnson syndrome and toxic epidermal necrolysis. Curr Opin Allergy Clin Immunol. 2023 Aug 1;23(4):271-278. doi: 10.1097/ACI.0000000000000914. Epub 2023 Jun 6. PMID: 37284785.
  219. Okamoto-Uchida Y, Nakamura R, Sai K, Imatoh T, Matsunaga K, Aihara M, Saito Y. Effect of Infectious Diseases on the Pathogenesis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Biol Pharm Bull. 2017;40(9):1576-1580. doi: 10.1248/bpb.b17-00207. PMID: 28867742.
  220. Sadek M, Iqbal O, Siddiqui F, Till S, Mazariegos M, Campbell E, Mudaliar K, Speiser J, Bontekoe E, Kouta A, Farooqui A, Daravath B, Qneibi D, Sadek R, Hoppensteadt D, Fareed J, Bouchard C. The Role of IL-13, IL-15 and Granulysin in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Clin Appl Thromb Hemost. 2021 Jan-Dec;27:1076029620950831. doi: 10.1177/1076029620950831. PMID: 33560872; PMCID: PMC7876748.
  221. Shah H, Parisi R, Mukherjee E, Phillips EJ, Dodiuk-Gad RP. Update on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Diagnosis and Management. Am J Clin Dermatol. 2024 Nov;25(6):891-908. doi: 10.1007/s40257-024-00889-6. Epub 2024 Sep 15. PMID: 39278968; PMCID: PMC11511757.
  222. Makihara H, Maezawa M, Kaiga K, Satake T, Muto M, Tsunoda Y, Shimada T, Akase T. mRNA expression levels of cytochrome P450 CYP1A2, CYP3A4, and CYP3A5 in the epidermis: a focus on individual differences among Japanese individuals. Xenobiotica. 2024 May;54(5):226-232. doi: 10.1080/00498254.2024.2344664. Epub 2024 Apr 24. PMID: 38646717.
  223. Shiravand Y, Khodadadi F, Kashani SMA, Hosseini-Fard SR, Hosseini S, Sadeghirad H, Ladwa R, O'Byrne K, Kulasinghe A. Immune Checkpoint Inhibitors in Cancer Therapy. Curr Oncol. 2022 Apr 24;29(5):3044-3060. doi: 10.3390/curroncol29050247. PMID: 35621637; PMCID: PMC9139602.
  224. Tan S, Day D, Nicholls SJ, Segelov E. Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2022 Dec 20;4(5):579-597. doi: 10.1016/j.jaccao.2022.09.004. PMID: 36636451; PMCID: PMC9830229.
  225. Arafat Hossain M. A comprehensive review of immune checkpoint inhibitors for cancer treatment. Int Immunopharmacol. 2024 Dec 25;143(Pt 2):113365. doi: 10.1016/j.intimp.2024.113365. Epub 2024 Oct 23. PMID: 39447408.
  226. Mc Neil V, Lee SW. Advancing Cancer Treatment: A Review of Immune Checkpoint Inhibitors and Combination Strategies. Cancers (Basel). 2025 Apr 23;17(9):1408. doi: 10.3390/cancers17091408. PMID: 40361336; PMCID: PMC12071127.
  227. Dara L, De Martin E. Immune-Mediated Liver Injury From Checkpoint Inhibitor: An Evolving Frontier With Emerging Challenges. Liver Int. 2025 Feb;45(2):e16198. doi: 10.1111/liv.16198. PMID: 39868913; PMCID: PMC11771569.
  228. Marei HE, Hasan A, Pozzoli G, Cenciarelli C. Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired. Cancer Cell Int. 2023 Apr 10;23(1):64. doi: 10.1186/s12935-023-02902-0. PMID: 37038154; PMCID: PMC10088229.
  229. Hountondji L, Ferreira De Matos C, Lebossé F, Quantin X, Lesage C, Palassin P, Rivet V, Faure S, Pageaux GP, Assenat É, Alric L, Zahhaf A, Larrey D, Witkowski Durand Viel P, Riviere B, Janick S, Dalle S, Maria ATJ, Comont T, Meunier L. Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. JHEP Rep. 2023 Mar 7;5(6):100719. doi: 10.1016/j.jhepr.2023.100719. PMID: 37138674; PMCID: PMC10149360.
  230. Meunier L, Hountondji L, Jantzem H, Faillie JL, Maria A, Palassin P; MonRIO group. Cholangitis Induced by Immune Checkpoint Inhibitors: Analysis of Pharmacovigilance Data. Clin Gastroenterol Hepatol. 2024 Jul;22(7):1542-1545.e4. doi: 10.1016/j.cgh.2023.12.008. Epub 2023 Dec 16. PMID: 38110061.
  231. Liu Z, Zhu Y, Xie H, Zou Z. Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. Front Pharmacol. 2023 Jan 9;13:1077468. doi: 10.3389/fphar.2022.1077468. PMID: 36699050; PMCID: PMC9868416.
  232. Cao R, Zhang S, Zhang J, Zhao Y, Zhang X, Guo Z. Treatment experience in managing severe immune-mediated hepatotoxicity induced by immune checkpoint inhibitors. Front Oncol. 2025 Oct 10;15:1657332. doi: 10.3389/fonc.2025.1657332. PMID: 41142624; PMCID: PMC12549241.
  233. Tsung I, Dolan R, Lao CD, Fecher L, Riggenbach K, Yeboah-Korang A, Fontana RJ. Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy. Aliment Pharmacol Ther. 2019 Oct;50(7):800-808. doi: 10.1111/apt.15413. Epub 2019 Jul 15. PMID: 31309615.
  234. Swanson LA, Kassab I, Tsung I, Schneider BJ, Fontana RJ. Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: A retrospective analysis. Front Oncol. 2022 Oct 24;12:984940. doi: 10.3389/fonc.2022.984940. PMID: 36353563; PMCID: PMC9637844.
  235. Zheng C, Huang S, Lin M, Hong B, Dai H, Yang J. Development and Validation of a Clinical Risk Score to Predict Immune-mediated Liver Injury Caused by Sintilimab: Assessed for Causality Using Updated RUCAM. J Clin Transl Hepatol. 2023 Nov 28;11(6):1387-1396. doi: 10.14218/JCTH.2023.00124. Epub 2023 Jul 7. PMID: 37719962; PMCID: PMC10500293.
  236. Regev A, Avigan MI, Kiazand A, Vierling JM, Lewis JH, Omokaro SO, Di Bisceglie AM, Fontana RJ, Bonkovsky HL, Freston JW, Uetrecht JP, Miller ED, Pehlivanov ND, Haque SA, Harrison MJ, Kullak-Ublick GA, Li H, Patel NN, Patwardhan M, Price KD, Watkins PB, Chalasani NP. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development. J Autoimmun. 2020 Nov;114:102514. doi: 10.1016/j.jaut.2020.102514. Epub 2020 Aug 5. PMID: 32768244.
  237. Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, Sznol M, Long GV, Li H, Waxman IM, Jiang J, Robert C. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol. 2017 Mar;35(7):785-792. doi: 10.1200/JCO.2015.66.1389. Epub 2016 Nov 14. PMID: 28068177.
  238. Da Cunha T, Wu GY, Vaziri H. Immunotherapy-induced Hepatotoxicity: A Review. J Clin Transl Hepatol. 2022 Dec 28;10(6):1194-1204. doi: 10.14218/JCTH.2022.00105. Epub 2022 Jul 22. PMID: 36381098; PMCID: PMC9634765.
  239. Haanen J, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, Lyon AR, Wick W, Kostine M, Peters S, Jordan K, Larkin J; ESMO Guidelines Committee. Electronic address: [email protected]. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022 Dec;33(12):1217-1238. doi: 10.1016/j.annonc.2022.10.001. Epub 2022 Oct 18. PMID: 36270461.
  240. Common Terminology Criteria for Adverse Events (CTCAE) v 5.0. 2017. Accessed 21 October 2025. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
  241. Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021 Dec 20;39(36):4073-4126. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 1. Erratum in: J Clin Oncol. 2022 Jan 20;40(3):315. doi: 10.1200/JCO.21.02786. PMID: 34724392.
  242. Colevas AD, Setser A. The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials. J Clin Oncol. 2004; 22: 6098. doi: 10.1200/jco.2004.22.90140.6098.
  243. Clinton JW, Kiparizoska S, Aggarwal S, Woo S, Davis W, Lewis JH. Drug-Induced Liver Injury: Highlights and Controversies in the Recent Literature. Drug Saf. 2021 Nov;44(11):1125-1149. doi: 10.1007/s40264-021-01109-4. Epub 2021 Sep 17. PMID: 34533782; PMCID: PMC8447115.
  244. Cheung V, Gupta T, Payne M, Middleton MR, Collier JD, Simmons A, Klenerman P, Brain O, Cobbold JF. Immunotherapy-related hepatitis: real-world experience from a tertiary centre. Frontline Gastroenterol. 2019 Oct;10(4):364-371. doi: 10.1136/flgastro-2018-101146. Epub 2019 Mar 22. PMID: 31656561; PMCID: PMC6788136.
  245. Malnick SDH, Abdullah A, Neuman MG. Checkpoint Inhibitors and Hepatotoxicity. Biomedicines. 2021 Jan 21;9(2):101. doi: 10.3390/biomedicines9020101. PMID: 33494227; PMCID: PMC7909829.
  246. Remash D, Prince DS, McKenzie C, Strasser SI, Kao S, Liu K. Immune checkpoint inhibitor-related hepatotoxicity: A review. World J Gastroenterol. 2021 Aug 28;27(32):5376-5391. doi: 10.3748/wjg.v27.i32.5376. PMID: 34539139; PMCID: PMC8409159.
  247. König D, Läubli H. Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors. Pharmacology. 2021;106(3-4):123-136. doi: 10.1159/000509081. Epub 2020 Jul 28. PMID: 32721966.
  248. Triantafyllou E, Gudd CLC, Possamai LA. Immune-mediated liver injury from checkpoint inhibitors: mechanisms, clinical characteristics and management. Nat Rev Gastroenterol Hepatol. 2025 Feb;22(2):112-126. doi: 10.1038/s41575-024-01019-7. Epub 2024 Dec 11. PMID: 39663461.
  249. Ahmed M. Checkpoint inhibitors: What gastroenterologists need to know. World J Gastroenterol. 2018 Dec 28;24(48):5433-5438. doi: 10.3748/wjg.v24.i48.5433. PMID: 30622372; PMCID: PMC6319137.

Comments

Swift, Reliable, and studious. We aim to cherish the world by publishing precise knowledge.

  • Brown University Library
  • University of Glasgow Library
  • University of Pennsylvania, Penn Library
  • University of Amsterdam Library
  • The University of British Columbia Library
  • UC Berkeley’s Library
  • MIT Libraries
  • Kings College London University
  • University of Texas Libraries
  • UNSW Sidney Library
  • The University of Hong Kong Libraries
  • UC Santa Barbara Library
  • University of Toronto Libraries
  • University of Oxford Library
  • Australian National University
  • ScienceOpen
  • UIC Library
  • KAUST University Library
  • Cardiff University Library
  • Ball State University Library
  • Duke University Library
  • Rutgers University Library
  • Air University Library
  • UNT University of North Texas
  • Washington Research Library Consortium
  • Penn State University Library
  • Georgetown Library
  • Princeton University Library
  • Science Gate
  • Internet Archive
  • WashingTon State University Library
  • Dimensions
  • Zenodo
  • OpenAire
  • Index Copernicus International
  • icmje
  • International Scientific Indexing (ISI)
  • Sherpa Romeo
  • ResearchGate
  • Universidad De Lima
  • WorldCat
  • JCU Discovery
  • McGill
  • National University of Singepore Libraries
  • SearchIT
  • Scilit
  • SemantiScholar
  • Base Search
  • VU
  • KB
  • Publons
  • oaji
  • Harvard University
  • sjsu-library
  • UWLSearch
  • Florida Institute of Technology
  • CrossRef
  • LUBsearch
  • Universitat de Paris
  • Technical University of Denmark
  • ResearchBIB
  • Google Scholar
  • Microsoft Academic Search